PFO
STML

Pathstone Family Office’s Stemline Therapeutics, Inc. STML Stock Holding History

Pathstone Family Office’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-91
Closed -$1K – 694
2017
Q1 		$1K Buy
+91
New +$829 ﹤0.01% 551

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Family Office's STML Position: Q2 2017 in Review

Pathstone Family Office sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 91 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in STML in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • Pathstone Family Office reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Pathstone Family Office sold 91 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $1K.
  • Pathstone Family Office first reported a position in Stemline Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • Pathstone Family Office's Stemline Therapeutics, Inc. position peaked at $1K in Q1 2017.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Pathstone Family Office's 13F filing for Q2 2017, filed 11 Aug 2017.